NASDAQ$NPCE
Neuropace Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
NeuroPace experienced revenue growth and maintained financial discipline.
NeuroPace reported a 25% increase in revenue to $18.1 million for Q1 2024 compared to Q1 2023. The company's gross margin was 73.6%, and it extended the maturity date of its term loan by one year to September 30, 2026. The company maintained full-year 2024 revenue guidance of $73 to $77 million.
- Total revenue increased by 25% year-over-year to $18.1 million.
- Gross margin improved to 73.6% compared to 71.7% in the prior year.
- The company extended the maturity date of its term loan by one year to September 30, 2026.
- Full-year 2024 revenue guidance is maintained at $73 to $77 million.
Headline financials
Revenue & EPS history
Neuropace · Revenue · Quarterly
$18.1M
Revenue by segment
Neuropace · $1.6M total across 1 segment · Q4 2022
- DIXI Medical$1.6M—100.0%
Forward guidance
NeuroPace expects revenue growth to be primarily driven by increasing sales of its RNS System and higher sales of DIXI Medical stereo EEG products, while replacement implant revenue is expected to decline in 2024 versus 2023. Total revenue to range between $73 million and $77 million, representing growth of 12% to 18% over 2023. Gross margin to range between 72% and 74%. Total operating expenses to range between $80 million and $84 million, including approximately $12 million in stock-based compensation, a noncash expense
Tailwinds
- Revenue growth to be driven by RNS System sales increases.
- Higher sales of DIXI Medical stereo EEG products expected.
- Full year revenue to range between $73 million and $77 million.
- Revenue growth of 12% to 18% over 2023 expected.
- Gross margin to range between 72% and 74%.
Headwinds
- Replacement implant revenue is expected to decline in 2024 versus 2023.
- Total operating expenses to range between $80 million and $84 million.
- Includes approximately $12 million in stock-based compensation, a noncash expense.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2024
-0.7%
Avg return
Earnings day
-1.0%
Avg return
5 days after
-0.1%
Avg return
30 days after
50%
12 / 24 earnings
Positive
+37.4%
Q3 2025
Best reaction
-40.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.6% | -1.8% | — | |
| Q4 2025 | +1.1% | +1.6% | +5.9% | |
| Q3 2025 | +37.4% | +43.1% | +74.5% | |
| Q1 2025 | +21.6% | +31.3% | -14.5% | |
| Q4 2024 | -2.4% | -15.8% | +2.6% | |
| Q3 2024 | +25.7% | +23.4% | +49.9% | |
| Q2 2024 | -1.9% | -0.4% | +4.8% | |
| Q1 2024 | -40.1% | -35.9% | -51.4% | |
| Q4 2023 | +0.8% | +2.5% | -8.4% | |
| Q3 2023 | -1.4% | +9.5% | +14.6% | |
| Q2 2023 | +9.8% | +9.8% | +103.4% | |
| Q1 2023 | +1.9% | -3.5% | -15.4% | |
| Q4 2022 | -13.3% | -7.8% | -1.9% | |
| Q3 2022 | -9.9% | -17.6% | -29.6% | |
| Q2 2022 | -3.5% | -10.2% | -26.6% | |
| Q1 2022 | +1.2% | -3.6% | -3.8% | |
| Q4 2021 | -0.9% | -7.7% | -1.2% | |
| Q3 2020 | -15.2% | -22.2% | -47.7% | |
| Q3 2021 | -15.2% | -22.2% | -47.7% | |
| Q2 2021 | -7.6% | -10.7% | -8.0% | |
| Q2 2020 | -7.6% | -10.7% | -8.0% | |
| Q1 2020 | +0.8% | +8.7% | +2.2% | |
| Q1 2021 | +0.8% | +8.7% | +2.2% | |
| Q4 2020 | +0.8% | +8.7% | +2.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro